Quality of Life-Guided Transfusion in Refractory MDS or AML

Patients with refractory myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) in exclusive palliative care frequently receive red blood cell transfusions based on hemoglobin thresholds, despite limited evidence of clinical benefit in this setting. This prospective randomized study compares a standard hemoglobin-based transfusion strategy to a quality-of-life-guided strategy using the EQ-5D-5L questionnaire, with the aim of reducing transfusion burden while maintaining patient safety and quality of life.

NCT Number	NCT07328191
Lead Sponsor	Centre Hospitalier Universitaire de Nice
Conditions	MDS, AML, Adult, Anemia
Enrollment	52 participants
Start Date	2026-02-09
Primary Completion	2027-02-09 (estimated)
Study Completion	2028-02-09 (estimated)
Updated on ClinicalTrials.gov	2026-02-12